Once is not enough: clinical trials in sepsis

[1] Bertolini G(2007)Use of Drotrecogin alfa (activated) in Italian intensive care units: the results of a nationwide survey Intensive Care Med 33 426-434

[2] Rossi C(2007)Evaluating the use of Drotrecogin alfa (activated) in adult severe sepsis: a Canadian multicenter observational study Intensive Care Med 33 517-523

[3] Anghileri A(2007)REsearching severe sepsis, organ dysfunction in children: a global perspective (RESOLVE) study group Drotrecogin alfa (activated) in children with severe sepsis: multicentre phase III randomised controlled trial Lancet 369 836-843

[4] Livigni S(2008)Drotrecogin alfa (activated): real-life use and outcomes for the UK Crit Care 12 R58-665

[5] Addis A(1987)Effect of high-dose glucocorticoid therapy on mortality in patients with clinical signs of systemic sepsis N Engl J Med 317 659-240

[6] Poole D(1992)Prophylactic intravenous administration of standard immune globulin as compared with core-lipopolysaccharide immune globulin in patients at high risk of postsurgical infection N Engl J Med 327 234-701

[7] Kanji S(1992)Treatment of severe infectious purpura in children with human plasma from donors immunized with J Infect Dis 165 695-1341

[8] Perreault MM(2005) J5: a prospective double-blind study N Engl J Med 353 1332-63

[9] Chant C(1985)Administration of Drotrecogin Alfa (activated) in Early Stage Severe Sepsis (ADDRESS) Study Group Drotrecogin alfa (activated) for adults with severe sepsis and a low risk of death Lancet 2 59-465

[10] Williamson D(1963)Prevention of gram-negative shock and death in surgical patients by antibody to endotoxin core glycolipid JAMA 183 462-2059

[1] Bertolini G(2007)Use of Drotrecogin alfa (activated) in Italian intensive care units: the results of a nationwide survey Intensive Care Med 33 426-434

[2] Rossi C(2007)Evaluating the use of Drotrecogin alfa (activated) in adult severe sepsis: a Canadian multicenter observational study Intensive Care Med 33 517-523

[3] Anghileri A(2007)REsearching severe sepsis, organ dysfunction in children: a global perspective (RESOLVE) study group Drotrecogin alfa (activated) in children with severe sepsis: multicentre phase III randomised controlled trial Lancet 369 836-843

[4] Livigni S(2008)Drotrecogin alfa (activated): real-life use and outcomes for the UK Crit Care 12 R58-665

[5] Addis A(1987)Effect of high-dose glucocorticoid therapy on mortality in patients with clinical signs of systemic sepsis N Engl J Med 317 659-240

[6] Poole D(1992)Prophylactic intravenous administration of standard immune globulin as compared with core-lipopolysaccharide immune globulin in patients at high risk of postsurgical infection N Engl J Med 327 234-701

[7] Kanji S(1992)Treatment of severe infectious purpura in children with human plasma from donors immunized with J Infect Dis 165 695-1341

[8] Perreault MM(2005) J5: a prospective double-blind study N Engl J Med 353 1332-63

[9] Chant C(1985)Administration of Drotrecogin Alfa (activated) in Early Stage Severe Sepsis (ADDRESS) Study Group Drotrecogin alfa (activated) for adults with severe sepsis and a low risk of death Lancet 2 59-465

[10] Williamson D(1963)Prevention of gram-negative shock and death in surgical patients by antibody to endotoxin core glycolipid JAMA 183 462-2059